Mereo BioPharma Group (NASDAQ:MREO) Given New $1.00 Price Target at BTIG Research

Mereo BioPharma Group (NASDAQ:MREO) had its price objective trimmed by BTIG Research from $6.00 to $1.00 in a research note published on Monday, MarketBeat Ratings reports. The firm currently has a buy rating on the stock.

MREO has been the subject of several other reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Mereo BioPharma Group in a research report on Monday. Needham & Company LLC reiterated a “buy” rating and issued a $5.00 price objective on shares of Mereo BioPharma Group in a report on Monday, December 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Mereo BioPharma Group in a report on Wednesday, October 8th. Finally, Zacks Research raised shares of Mereo BioPharma Group from a “strong sell” rating to a “hold” rating in a research note on Wednesday, November 12th. Four equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Mereo BioPharma Group currently has a consensus rating of “Hold” and an average target price of $4.40.

Mereo BioPharma Group Stock Performance

NASDAQ MREO opened at $0.29 on Monday. The firm’s fifty day moving average price is $1.94 and its two-hundred day moving average price is $1.98. The stock has a market cap of $46.15 million, a PE ratio of -4.83 and a beta of 0.45. Mereo BioPharma Group has a fifty-two week low of $0.20 and a fifty-two week high of $3.84.

Mereo BioPharma Group (NASDAQ:MREO) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.01) EPS for the quarter. As a group, sell-side analysts predict that Mereo BioPharma Group will post -0.03 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Mereo BioPharma Group

Several hedge funds and other institutional investors have recently bought and sold shares of MREO. Marex Group plc acquired a new position in Mereo BioPharma Group during the 2nd quarter worth approximately $27,000. State of New Jersey Common Pension Fund D bought a new stake in shares of Mereo BioPharma Group during the third quarter valued at approximately $32,000. Virtu Financial LLC acquired a new position in shares of Mereo BioPharma Group during the third quarter worth approximately $33,000. Significant Wealth Partners LLC lifted its holdings in shares of Mereo BioPharma Group by 61.7% in the 2nd quarter. Significant Wealth Partners LLC now owns 22,261 shares of the company’s stock worth $60,000 after purchasing an additional 8,490 shares in the last quarter. Finally, Squarepoint Ops LLC grew its position in Mereo BioPharma Group by 45.4% in the 3rd quarter. Squarepoint Ops LLC now owns 30,055 shares of the company’s stock valued at $62,000 after purchasing an additional 9,387 shares during the period. Institutional investors and hedge funds own 62.83% of the company’s stock.

Key Mereo BioPharma Group News

Here are the key news stories impacting Mereo BioPharma Group this week:

• Positive Sentiment: Mereo said it is implementing cost controls and provided program updates that may reduce cash burn and extend runway while the company assesses next steps. Article Title
• Positive Sentiment: Some analysts (BTIG) maintained a constructive stance by keeping a “buy” rating despite slashing their price target, which could suggest selective investor support if management outlines a credible recovery plan. Article Title
• Neutral Sentiment: Trading in MREO was temporarily halted for “news pending,” a routine market-protection step that concentrated selling once the halt lifted. (Trading halt reported 08:25 AM on 12/29.)
• Neutral Sentiment: LifeSci Capital had earlier reaffirmed a “market perform” rating, reflecting caution prior to the trial results and signaling mixed analyst views. Article Title
• Negative Sentiment: Mereo announced that both Phase 3 ORBIT and COSMIC failed to achieve their primary endpoint of reducing annualized clinical fracture rate versus placebo or bisphosphonates — a direct hit to the commercial outlook for setrusumab. Article Title
• Negative Sentiment: Following the trial news, LifeSci Capital officially downgraded Mereo, adding analyst pressure and reducing investor confidence. Article Title
• Negative Sentiment: Broad market coverage highlights the stock plunge and investor losses; commentary and sell-side note circulation (AAII, Investing.com, Benzinga) have amplified selling pressure. Article Title
• Negative Sentiment: BTIG cut its price target sharply (from $6.00 to $1.00), signaling much lower near-term valuation expectations despite retaining a buy rating; that PT cut likely weighs on sentiment. Article Title

Mereo BioPharma Group Company Profile

Mereo BioPharma Group plc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for rare diseases, oncology and severe respiratory conditions. The company pursues an asset‐centric model, in which it in-licenses or acquires clinical-stage small molecules and monoclonal antibodies with established safety profiles. By concentrating resources on a select number of programs, Mereo aims to accelerate proof-of-concept studies and maximize the potential value of each therapeutic candidate.

Mereo’s pipeline includes investigational therapies for skeletal disorders, such as setrusumab (BPS-804) for osteogenesis imperfecta, and treatments for acute and chronic respiratory diseases.